Thomas R. Parr holds the position of Chief Scientific Officer at Spero Therapeutics, Inc.

In his past career Dr. Parr occupied the position of President & Acting Chief Executive Officer at MicroGenomics, Inc., Chief Scientific Officer at Fedora Pharmaceuticals, Inc., Vice President-Research at Adaptive Therapeutics, Inc., Chief Scientific Officer & Head-Montreal Site at Targanta Therapeutics Corp., Chief Scientific Officer at Targanta Therapeutics, Inc., Principal at Essential Therapeutics, Inc., Senior Director-Microbiology at IntraBiotics Pharmaceuticals, Inc., Senior Director-Microbiology at Xenogen Corp., Principal at Lilly Research Laboratories and Assistant Professor at the University of Ottawa.

Dr. Parr received a graduate degree and a doctorate from the University of Calgary and an undergraduate degree from the University of Minnesota.